Dr. Alan Jacobs M.D., Ph.D., Founder and President of PerceptiMed that was founded in 2011 with a driving purpose — to reduce the margin of human error in prescription pill dispensing in retail pharmacies, long-term care facilities and hospitals joins eHealth Radio and the Health News and Pharmaceutical Channels.
Listen to interview with host Eric Michaels & guest Dr. Alan Jacobs discuss the following:
- Can you explain the situation involving your father-in-law that led you to start PerceptiMed?
- What feelings ran through your head when you discovered that a medication error threatened a loved one’s life?
- As a physician, were you surprised to uncover the prevalence of medication errors?
- What is the mission of PerceptiMed?
- Can you give us a background on IdentRx and the impact you see it making on the healthcare industry?
- How does the Ident-Rx remote allow PerceptiMed to service patients in rural areas?
- How can MedPass be a valuable asset to hospitals and long-term care facilities?
- What is ScripClip and how can ScripClip be a valuable technology for pharmacies?
- If you could give any advice to people for them to self-identify medications, what would that be?
Alan Jacobs, M.D., Ph.D., the President, CTO & Founder of PerceptiMed is driven to reduce the margin of human error in the administration of prescription drugs. As such, he has focused on creating “first-in-class” technology that eliminates medication errors in retail pharmacies, long-term care facilities and hospitals.
He holds several key patents and is the co-inventor of the IdentRx™ medication verification system. Alan has extensive experience leading international teams in the research and development of therapeutics and medical devices. He began his research and development career at Elan Pharmaceuticals where he designed and managed clinical drug trials, drug development protocols and safety infrastructures for investigating treatments of traumatic brain injury and peri-operative pain management. Dr. Jacobs has also led the clinical development of novel therapeutics at Layton BioScience and Titan Pharmaceuticals before serving as CMO and Vice President of Clinical Research at Stem Cells, Inc., where he led the clinical team developing novel treatments for Batten’s disease.
Alan received a B.S.E.E. from Cornell University and a M.S.E.E from Stanford University. He also holds a Medical Doctorate from the School of Medicine at University of Pennsylvania and a Ph.D. from the David Mahoney Institute of Neuroscience, University Pennsylvania, where he was a Fellow, in the Medical Scientist Training Program of the National Institute of General Medical Sciences. Alan completed an internship in General Surgery and was a resident in Neurological Surgery at the University of California, San Francisco Medical Center.